Furthermore, VSL#3 interacts with hMSCs in suppressing the NLRP3 inflammasome, exerting central and peripheral anti-inflammatory effects to exert neuroprotective actions in PD mice, providing evidence for the potential of VSL#3 as an adjuvant therapy in PD treatment. This evidence concerns the gene NLRP3 and Parkinson disease.